Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) shares saw unusually-high trading volume on Monday . Approximately 902,606 shares were traded during trading, an increase of 921% from the previous session’s volume of 88,409 shares.The stock last traded at $5.82 and had previously closed at $4.50.

GLMD has been the topic of a number of analyst reports. Maxim Group reaffirmed a “buy” rating and set a $10.00 price objective on shares of Galmed Pharmaceuticals in a research note on Thursday, November 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Galmed Pharmaceuticals in a research note on Friday, October 18th. ValuEngine cut shares of Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Canaccord Genuity initiated coverage on shares of Galmed Pharmaceuticals in a research note on Monday. They issued a “buy” rating on the stock. Finally, HC Wainwright reissued a “buy” rating on shares of Galmed Pharmaceuticals in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $25.79.

The business’s 50 day moving average is $4.20 and its 200-day moving average is $5.40. The stock has a market cap of $105.10 million, a price-to-earnings ratio of -10.78 and a beta of 2.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 22.78 and a current ratio of 22.78.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.11. Sell-side analysts anticipate that Galmed Pharmaceuticals Ltd will post -0.93 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Delek Group Ltd. boosted its stake in Galmed Pharmaceuticals by 15.5% during the 2nd quarter. Delek Group Ltd. now owns 24,552 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 3,300 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Galmed Pharmaceuticals by 796.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,207 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 4,626 shares during the last quarter. ARK Investment Management LLC boosted its stake in Galmed Pharmaceuticals by 13.4% during the 2nd quarter. ARK Investment Management LLC now owns 60,948 shares of the biopharmaceutical company’s stock worth $448,000 after purchasing an additional 7,199 shares during the last quarter. Morgan Stanley boosted its stake in Galmed Pharmaceuticals by 132.1% during the 2nd quarter. Morgan Stanley now owns 14,783 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 8,414 shares during the last quarter. Finally, ETF Managers Group LLC boosted its stake in Galmed Pharmaceuticals by 34.7% during the 2nd quarter. ETF Managers Group LLC now owns 45,222 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 11,649 shares during the last quarter. 30.11% of the stock is currently owned by institutional investors.

Galmed Pharmaceuticals Company Profile (NASDAQ:GLMD)

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

Read More: What Does Beta Mean In Stock Selection?

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.